Sugi Predict

Sugi Predict / Compounds / SCHEMBL2907458

SCHEMBL2907458

SCHEMBL2907458

c1ccc2nc(-c3cc[nH]n3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 10/20 0.47
▸ ALDH1A1 P00352 9/20 0.47
▸ NPC1 O15118 9/20 0.47
▸ KDM4E B2RXH2 8/20 0.47
▸ HPGD P15428 5/20 0.47
▸ SMN1; SMN2 Q16637 5/20 0.47
▸ PKM P14618 4/20 0.47
▸ HSD17B10 Q99714 4/20 0.47
▸ TP53 P04637 4/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ CYP3A4 P08684 3/20 0.47
▸ CYP1A2 P05177 3/20 0.47
▸ AR P10275 3/20 0.47
▸ CYP2D6 P10635 2/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ GFER P55789 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29746199 1.00 RAB9A (0.47) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL170196 0.81 RAB9A (0.64) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL29374931 0.81 RAB9A (0.64) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL10866984 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL31365172 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD
Hydrochloric Acid SCHEMBL31243061 0.79 ALDH1A1 (0.63) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL30883993 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL34463709 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL31490600 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD
SCHEMBL30883995 0.79 RAB9A (0.61) RAB9AALDH1A1NPC1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689627-B Pyrazolylquinoline compounds, process for their preparation and pharmaceutical compositions containing them 高雄医学大学 2022-10-11 — — CN claimed
CN-109689627-A Pyrazolyl quinoline compound and preparation method thereof and medical component 高雄医学大学 2019-04-26 — — CN claimed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 — — US disclosed
CN-120623147-B Pyrazolyl quinoline ether compound and application thereof in preparation of neuroprotective drugs 广东省科学院动物研究所 2025-12-16 — — CN disclosed
CN-120623147-A Pyrazolyl quinoline ether compound and application thereof in preparation of neuroprotective drugs 广东省科学院动物研究所 2025-09-12 — — CN disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 — — EP disclosed
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2024-04-11 — — US disclosed
WO-2023249106-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS 東レ株式会社 2023-12-28 — — WO disclosed
WO-2023249105-A1 THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS 東レ株式会社 2023-12-28 — — WO disclosed
WO-2023249107-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER 東レ株式会社 2023-12-28 — — WO disclosed
WO-2007071632-A2 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES NEUROSEARCH A/S (DK) 2007-06-28 — — WO disclosed
EP-1565471-B1 QUINOLINYL-PYRROLOPYRAZOLES LILLY CO ELI (US) 2006-10-04 — — EP disclosed
US-20060040983-A1 Quinolinyl-pyrrolopyrazoles ELI LILLY AND COMPANY (US) 2006-02-23 — — US disclosed
CN-1714090-A Quinolinyl-pyrrolopyrazoles LILLY CO ELI (US) 2005-12-28 — — CN disclosed
EP-1565471-A1 QUINOLINYL-PYRROLOPYRAZOLES ELI LILLY AND COMPANY (US) 2005-08-24 — — EP disclosed
WO-2004048382-A1 QUINOLINYL-PYRROLOPYRAZOLES ELI LILLY AND COMPANY (US) 2004-06-10 — — WO disclosed
WO-2001002385-A1 1-(QUINOLIN-4-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE AS FUNGICIDES AVENTIS CROPSCIENCE S.A. (FR) 2001-01-11 — — WO disclosed
US-5561234-A EXHIBIT HIGH AFFINITY FOR THE NEUROTENSIN RECEPTOR SANOFI (FR) 1996-10-01 — — US disclosed
EP-0695747-A1 Derivatives of substituted N-oxide 1-(7-chloroquinolin-4-yl)pyrozole-3-carboxamides as ligand of the neurotensin receptor SANOFI (FR) 1996-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF AIFM2, TXNRD2, NFE2L2 RAB9A 1151/4885ALDH1A1 2714/4885NPC1 579/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 RAB9A 1524/4885ALDH1A1 2086/4885NPC1 532/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 RAB9A 1155/4885ALDH1A1 3280/4885NPC1 134/4885
US-20060040983-A1 Quinolinyl-pyrrolopyrazoles SDHA, NQO2, SDHB RAB9A 656/4885ALDH1A1 1130/4885NPC1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.